Lupus & antiphospholipid syndrome
Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states
Authors' conclusion
Our comprehensive transcriptomic study revealed gene expression signatures for SLE in both active and remission states.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE) in remission or flare, and healthy controls
- Participants
- 26 / 76 / 15
- Comparison
- SLE in remission vs SLE flares vs healthy controls
- Remissionn = 26
- Flaresn = 76
- Healthy controlsn = 15reference
- Outcome
- Transcriptomic signatures and dysregulated pathways in PBMCs across disease states, particularly those persisting during remission
Methodological detailsbulk RNA-sequencing of peripheral blood mononuclear cells (PBMCs), differentially expressed genes and pathways, protein-protein interaction networks, drug repurposing analysis
- Bulk RNA-sequencing of PBMCs
- Differentially expressed genes and pathways
- Protein-protein interaction networks
- Drug repurposing analysis
Main finding
As reported in the abstract
Transcriptomic signatures across disease states
- Recovered in remission vs active disease: down-regulation of plasma and cell cycle signatures, up-regulation of lymphocytes
- Persisting across disease states: innate immune response signatures such as the interferon (IFN) signature, and gene modules involved in chromatin structure modification
- Drug repurposing analysis revealed certain drug classes that can target these persistent signatures
Original publication
Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states. Arthritis Res Ther. Published 13 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →